Concepedia

Author

B. Valenza

Hôpital Cochin

Also Known As

B Valenza, B. Valenza, Bruno Valenza

17

Publications

482

Citations

9

H-Index

23

Concepts

All Affiliations

Hôpital CochinUniversité Paris CitéAssistance Publique – Hôpitaux de ParisSorbonne UniversitéHôpital Saint-Louis
BV

About

B. Valenza is an author at Hôpital Cochin specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

357

2

Public Health

1

1

163

3

Epidemiology

1

1

163

4

Obstetrics

1

1

12

5

Pathology

1

1

17

B. Valenza

×

8

Publications

420

Citations

8

H-Index

YearCitations

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard,

European Journal of Cancer

2020

163

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled,

The Lancet

2019

125

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Pascal Piedbois, D. Serin, Franck Priou,

Annals of Oncology

2006

40

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

Jean-­Marc Ferrero, Cyril Foa, Simon Thézenas,

Oncology

2004

31

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD

Thomas Aparicio, Ariane Darut‐Jouve, F. Khemissa Akouz,

Journal of Geriatric Oncology

2020

21

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Yves Rinaldi, Anne‐Laure Pointet, F. Khemissa Akouz,

European Journal of Cancer

2020

17

Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy

R. Largillier, B. Valenza, J-M Ferrero,

Oncology

2007

12

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Dominique Berton, Anne Floquet, W. Lescaut,

Frontiers in Pharmacology

2021

11

Page 1